Spread of lymph node metastasis and adjuvant therapy for distal cholangiocarcinoma.
Bile duct cancer
Effectiveness of lymph node dissection
Efficacy index
Station of lymph node
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
16
02
2022
accepted:
12
04
2022
pubmed:
12
5
2022
medline:
23
6
2022
entrez:
11
5
2022
Statut:
ppublish
Résumé
Lymphatic metastasis is a major route of metastasis in distal cholangiocarcinoma (DCC). The present study aimed to elucidate the pattern of lymph node (LN) metastasis and the effectiveness of LN dissection and postoperative adjuvant chemotherapy in patients with DCC. Patients who underwent surgical resection with curative intent for DCC were enrolled. The nomenclature of the LN stations was defined according to the Japanese Society of Hepato-Biliary-Pancreatic Surgery guidelines. Effectiveness of LN dissection of each station was calculated using frequency of LN metastasis to the station and 5-year survival rate of patients with LN metastasis to that station. Of the 105 patients included in the study, 46 (43.8%) had LN metastasis, and 43 (41.0%) underwent postoperative adjuvant therapy. LN metastasis, serum carbohydrate antigen (CA) 19-9 level > 37 U/mL, and positive bile duct margin were independent risk factors for shorter overall survival (OS). The most common metastatic LN station at surgery was No. 13 (32.7%), followed by No. 12 (19.2%), No. 17 (9.6%), and No. 8 (6.6%). There was no effectiveness of LN dissection of the station No. 8, 14, and 16. Adjuvant chemotherapy was significantly associated with longer OS in patients with LN metastasis but not in those with positive ductal margins or serum CA 19-9 level > 37 U/mL. Postoperative adjuvant chemotherapy was associated with a better prognosis in patients with DCC and LN metastasis. However, a more effective therapeutic strategy is required to improve the prognosis of patients with other negative prognostic factors.
Sections du résumé
BACKGROUND
BACKGROUND
Lymphatic metastasis is a major route of metastasis in distal cholangiocarcinoma (DCC). The present study aimed to elucidate the pattern of lymph node (LN) metastasis and the effectiveness of LN dissection and postoperative adjuvant chemotherapy in patients with DCC.
METHODS
METHODS
Patients who underwent surgical resection with curative intent for DCC were enrolled. The nomenclature of the LN stations was defined according to the Japanese Society of Hepato-Biliary-Pancreatic Surgery guidelines. Effectiveness of LN dissection of each station was calculated using frequency of LN metastasis to the station and 5-year survival rate of patients with LN metastasis to that station.
RESULTS
RESULTS
Of the 105 patients included in the study, 46 (43.8%) had LN metastasis, and 43 (41.0%) underwent postoperative adjuvant therapy. LN metastasis, serum carbohydrate antigen (CA) 19-9 level > 37 U/mL, and positive bile duct margin were independent risk factors for shorter overall survival (OS). The most common metastatic LN station at surgery was No. 13 (32.7%), followed by No. 12 (19.2%), No. 17 (9.6%), and No. 8 (6.6%). There was no effectiveness of LN dissection of the station No. 8, 14, and 16. Adjuvant chemotherapy was significantly associated with longer OS in patients with LN metastasis but not in those with positive ductal margins or serum CA 19-9 level > 37 U/mL.
CONCLUSIONS
CONCLUSIONS
Postoperative adjuvant chemotherapy was associated with a better prognosis in patients with DCC and LN metastasis. However, a more effective therapeutic strategy is required to improve the prognosis of patients with other negative prognostic factors.
Identifiants
pubmed: 35543887
doi: 10.1007/s10147-022-02175-z
pii: 10.1007/s10147-022-02175-z
doi:
Substances chimiques
CA-19-9 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1212-1221Subventions
Organisme : Ministry of Health, Labour and Welfare
ID : 20K21633
Informations de copyright
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Références
Razumilava N, Gores GJ (2014) Cholangiocarcinoma. Lancet 383:2168–2179
doi: 10.1016/S0140-6736(13)61903-0
Al Mahjoub A, Bouvier V, Menahem B et al (2019) Epidemiology of intrahepatic, perihilar, and distal cholangiocarcinoma in the French population. Eur J Gastroenterol Hepatol 31:678–684
doi: 10.1097/MEG.0000000000001337
Ercolani G, Dazzi A, Giovinazzo F et al (2015) Intrahepatic, peri-hilar and distal cholangiocarcinoma: three different locations of the same tumor or three different tumors? Eur J Surg Oncol 41:1162–1169
doi: 10.1016/j.ejso.2015.05.013
Andrianello S, Paiella S, Allegrini V et al (2015) Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results, prognostic factors, and long-term follow-up. Langenbecks Arch Surg 400:623–628
doi: 10.1007/s00423-015-1320-0
Murakami Y, Uemura K, Hayashidani Y et al (2015) Prognostic impact of lymph node metastasis in distal cholangiocarcinoma. Br J Surg 102:399–406
doi: 10.1002/bjs.9799
Li X, Lin H, Sun Y et al (2019) Prognostic significance of the lymph node ratio in surgical patients with distal cholangiocarcinoma. J Surg Res 236:2–11
doi: 10.1016/j.jss.2018.10.044
Chung MJ, Lee KJ, Bang S et al (2011) Preoperative serum CA 19–9 level as a predictive factor for recurrence after curative resection in biliary tract cancer. Ann Surg Oncol 18:1651–1656
doi: 10.1245/s10434-010-1529-7
Murakami Y, Uemura K, Sudo T et al (2011) Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol 18:651–658
doi: 10.1245/s10434-010-1325-4
Kurahara H, Maemura K, Mataki Y et al (2017) Relationship between the surgical margin status, prognosis, and recurrence in extrahepatic bile duct cancer patients. Langenbecks Arch Surg 402:87–93
doi: 10.1007/s00423-016-1491-3
Chun YS, Pawlik TM, Vauthey JN (2018) 8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol 25:845–847. https://doi.org/10.1245/s10434-017-6025-x
doi: 10.1245/s10434-017-6025-x
pubmed: 28752469
Hester C, Nassour I, Adams-Huet B et al (2018) Improved survival in surgically resected distal cholangiocarcinoma treated with adjuvant therapy: a propensity score matched analysis. J Gastrointest Surg 22:2080–2087
doi: 10.1007/s11605-018-3875-x
Bergeat D, Turrini O, Courtin-Tanguy L et al (2018) Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort. Langenbecks Arch Surg 403:701–709
doi: 10.1007/s00423-018-1702-1
Messina C, Merz V, Frisinghelli M et al (2019) Adjuvant chemotherapy in resected bile duct cancer: a systematic review and meta-analysis of randomized trials. Crit Rev Oncol Hematol 143:124–129
doi: 10.1016/j.critrevonc.2019.09.002
Sasako M, McCulloch P, Kinoshita T et al (1995) New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 82:346–351
doi: 10.1002/bjs.1800820321
Imamura T, Yamamoto Y, Sugiura T et al (2021) Reconsidering the optimal regional lymph node station according to tumor location for pancreatic cancer. Ann Surg Oncol 28:1602–1611
doi: 10.1245/s10434-020-09066-5
Miyazaki M, Ohtsuka M, Miyakawa S et al (2015) Classification of biliary tract cancers established by the Japanese society of hepato-biliary-pancreatic surgery 3(rd) English edition. J Hepatobiliary Pancreat Sci 22:181–196
doi: 10.1002/jhbp.211
Neoptolemos JP, Moore MJ, Cox TF et al (2012) Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308:147–156
doi: 10.1001/jama.2012.7352
Ebata T, Hirano S, Konishi M et al (2018) Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 105:192–202
doi: 10.1002/bjs.10776
Edeline J, Benabdelghani M, Bertaut A et al (2019) Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase iii study. J Clin Oncol 37:658–667
doi: 10.1200/JCO.18.00050
Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20:663–673
doi: 10.1016/S1470-2045(18)30915-X
Furuse J, Okusaka T, Boku N et al (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849–855
doi: 10.1007/s00280-007-0673-7
Okusaka T, Ishii H, Funakoshi A et al (2006) Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57:647–653
doi: 10.1007/s00280-005-0095-3
Kobayashi S, Nagano H, Tomokuni A et al (2019) A prospective, randomized phase ii study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO 1208): kansai hepato-biliary oncology group. Ann Surg 270:230–237
doi: 10.1097/SLA.0000000000002865
Itano O, Takemura Y, Kishida N et al (2020) A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01). BMC Cancer 20:688. https://doi.org/10.1186/s12885-020-07185-6
doi: 10.1186/s12885-020-07185-6
pubmed: 32703191
pmcid: 7379785
Yadav S, Xie H, Bin-Riaz I et al (2019) Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis. Eur J Surg Oncol 45:1432–1438
doi: 10.1016/j.ejso.2019.03.023